乳腺癌pT1-2且1-3枚淋巴结转移患者术后放疗的预后影响:基于日本乳腺癌登记库的回顾性队列研究
基于日本国家临床数据库2004至2012年数据,纳入8914例pT1-2、N1且行乳房切除与腋窝淋巴结清扫的乳腺癌患者,比较接受术后放疗组(492例)与未接受组(8422例)。两组5年局部区域复发、任何复发及乳腺癌死亡发生率均无显著差异,多因素分析显示局部区域复发与肿瘤大小、淋巴结转移数目及三阴性亚型显著相关,而与术后放疗无关。
要点
- 术后放疗组与未放疗组5年局部区域复发率分别为4.0%与5.0%,差异无统计学意义(P=0.61)。
- 多因素分析显示局部区域复发与肿瘤大小、淋巴结转移数目及三阴性亚型显著相关,与术后放疗无关。
- 作者认为术后放疗的实施应结合肿瘤大小、3枚淋巴结转移及三阴性亚型的个体风险进行制定。
核心结论
- 在pT1-2且N1乳腺癌患者中,未放疗组5年局部区域复发率为5.0%,术后放疗未显著影响局部区域复发。
- 作者认为术后放疗的实施应结合肿瘤大小、3枚淋巴结转移和三阴性亚型的个体风险进行制定。
研究设计与样本
- 基于日本国家临床数据库2004至2012年数据的回顾性队列研究,共纳入8914例接受乳房切除与腋窝淋巴结清扫的pT1-2、N1乳腺癌患者。
- 术后放疗组492例,未放疗组8422例,中位观察时间6.3年,比较两组临床病理因素与预后。
主要发现
- 5年局部区域复发率术后放疗组4.0% vs 未放疗组5.0%,P=0.61。
- 5年任何复发率术后放疗组13.8% vs 未放疗组11.8%,P=0.23。
- 5年乳腺癌死亡率术后放疗组6.0% vs 未放疗组4.3%,P=0.08。
- 多因素分析显示局部区域复发与肿瘤大小、淋巴结转移数目及三阴性亚型显著相关,与术后放疗无关。
临床怎么用
- 作者认为术后放疗的实施应结合肿瘤大小、3枚淋巴结转移和三阴性亚型的个体风险进行制定。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Postmastectomy radiotherapy (PMRT) is the standard treatment for locally advanced breast cancer. However, the effectiveness of PMRT in patients with pT1-2 and N1 tumours remains controversial. Therefore, this study aimed to determine the prognostic impact of PMRT in patients with breast cancer and with pT1-2 and 1-3 lymph node metastases. METHODS: Using data from the Japanese National Clinical Database from 2004 to 2012, we evaluated the association of PMRT with locoregional recurrence (LRR), any recurrence, and mortality. We enrolled patients who had undergone mastectomy and axillary node dissection and were diagnosed with pT1-2 and N1. We compared clinicopathological factors and prognosis between patients who received (PMRT group) and those who did not receive (No-PMRT group) PMRT. RESULTS: Among 8914 patients enrolled, 492 patients belonged to the PMRT group and 8422 to the No-PMRT group. The median observation time was 6.3 years. There was no significant difference in the incidences of LRR (4.0% versus 5.0%, P = 0.61), recurrence (13.8% versus 11.8%, P = 0.23) and breast cancer death (6.0% versus 4.3%, P = 0.08) at 5 years between the groups. Multivariable analysis revealed that LRR was significantly associated with tumour size, number of node metastases and triple-negative subtype but not with PMRT. CONCLUSIONS: The LRR rate in the No-PMRT group was 5.0% at 5 years among patients with T1-2 and N1. PMRT did not significantly influence LRR in patients with T1-2 and N1. However, PMRT administration should be tailored considering the individual risks of tumour size, 3 node metastases and triple-negative subtype.
引用
- Yamada A, Hayashi N, Kumamaru H, et al. Prognostic impact of postoperative radiotherapy in patients with breast cancer and with pT1-2 and 1-3 lymph node metastases: A retrospective cohort study based on the Japanese Breast Cancer Registry. Eur J Cancer. 2022. PMID: 35752154. doi:10.1016/j.ejca.2022.05.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。